FIELD: medicine.
SUBSTANCE: disclosed is a screening method for detecting risk groups of developing a hypercoagulation state in conditions of expeditionary work in the Arctic. Venous blood is sampled from the expedition members, sailors and shift workers in the Arctic zone. Obtained blood samples are centrifuged at 3,000 rpm for 15 minutes. Automatic analyzer is used to determine the lag-phase time (tLag), the thrombin peak formation time (tPeak), the thrombin peak (Peak) and the endogenous thrombin potential (AUC). If the lag phase (tLag) is less than 7.8 minutes, the thrombin peak formation time (tPeak) is less than 16.7 minutes, the thrombin peak (Peak) is more than 153.7 nM, thrombin endogenous potential (AUC) of more than 1,735.9 nM of the person being tested is considered to be at risk of developing hypercoagulation in conditions of expeditionary work in Arctic.
EFFECT: invention provides objectification of the analyzed feature of hypercoagulation syndrome, increased diagnostic significance of the method and simplified interpretation of results, based on which a judgment is made on the possibility of the presence of hypercoagulation syndrome in conditions of expeditionary work in the Arctic.
1 cl, 2 dwg, 3 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR OPTIMIZING LABORATORY DIAGNOSIS OF THROMBINEMIA IN PATIENTS WITH COVID-19 INFECTION | 2022 |
|
RU2789822C1 |
METHOD FOR DIAGNOSING THROMBINEMIA IN PATIENTS WITH COVID-19 INFECTION | 2022 |
|
RU2794035C1 |
SCREENING-TEST OF DETERMINING COAGULATION CONTACT WAY (STOKPK) | 2017 |
|
RU2660706C1 |
METHOD FOR PREVENTION OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH MALIGNANT NEW GROWTH OF PROSTATE AFTER RADICAL PROSTATECTOMY | 2023 |
|
RU2815162C2 |
METHOD FOR PREDICTING RESUMPTION OF CORONARY HEART DISEASE CLINICAL PICTURE BY MEANS OF NEURAL NETWORKS IN PATIENTS AFTER ENDOVASCULAR INTERVENTION | 2017 |
|
RU2675067C1 |
METHOD FOR EVALUATING PLASMA HAEMOSTASIS | 2023 |
|
RU2816538C1 |
NOVEL COMPOUNDS POSSESSING ANTICOAGULANT FUNCTION, BASED ON THEM PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOTIC CONDITIONS AND PLASMA-SUBSTITUTING SOLUTION FOR CORRECTION OF HYPERCOAGULATION DISORDERS IN HEMODILUTION | 2007 |
|
RU2353619C2 |
HIGHLY-SELECTIVE INFESTIN 4-BASED INHIBITOR OF CONTACT ACTIVATION | 2013 |
|
RU2556116C2 |
TEST SYSTEM FOR PERFORMING HAEMOSTATIC PROPERTIES OF LOCAL WOUND COATINGS IN VITRO | 2019 |
|
RU2695075C1 |
DETERMINING OF CIRCULATING THROMBIN IN COMPLEMENT ACTIVATION TEST | 2019 |
|
RU2709341C1 |
Authors
Dates
2022-03-22—Published
2020-08-21—Filed